Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Brotschi

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Chemmedchem|September 16, 2020
The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia DisordersChristoph Boss, John Gatfield, Christine Brotschi, et al.
Journal of Medicinal Chemistry|February 13, 2024
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular ScaffoldCyrille Lescop, Christine Brotschi, Jodi T Williams, et al.
Chemmedchem|July 9, 2016
Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping ApproachBibia Heidmann, John Gatfield, Catherine Roch, et al.
Bioorganic & Medicinal Chemistry Letters|April 4, 2015
Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2Thierry Sifferlen, Amandine Boller, Audrey Chardonneau, et al.
Science Advances|March 1, 2024
A uniquely efficacious type of CFTR corrector with complementary mode of actionValentina Marchesin, Lucile Monnier, Peter Blattmann, et al.
Chemmedchem|August 23, 2014
Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonistChristoph Boss, Catherine Roch-Brisbare, Michel A Steiner, et al.
Bioorganic & Medicinal Chemistry Letters|January 23, 2014
Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1Thierry Sifferlen, Amandine Boller, Audrey Chardonneau, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 12, 2025
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosisMagdalena Birker-Robaczewska, Maxime Boucher, Giulia Ranieri, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Chemmedchem|September 16, 2020
The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia DisordersChristoph Boss, John Gatfield, Christine Brotschi, et al.
Journal of Medicinal Chemistry|February 13, 2024
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular ScaffoldCyrille Lescop, Christine Brotschi, Jodi T Williams, et al.
Chemmedchem|July 9, 2016
Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping ApproachBibia Heidmann, John Gatfield, Catherine Roch, et al.
Bioorganic & Medicinal Chemistry Letters|April 4, 2015
Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2Thierry Sifferlen, Amandine Boller, Audrey Chardonneau, et al.
Science Advances|March 1, 2024
A uniquely efficacious type of CFTR corrector with complementary mode of actionValentina Marchesin, Lucile Monnier, Peter Blattmann, et al.
Chemmedchem|August 23, 2014
Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonistChristoph Boss, Catherine Roch-Brisbare, Michel A Steiner, et al.
Bioorganic & Medicinal Chemistry Letters|January 23, 2014
Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1Thierry Sifferlen, Amandine Boller, Audrey Chardonneau, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 12, 2025
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosisMagdalena Birker-Robaczewska, Maxime Boucher, Giulia Ranieri, et al.
Pageof 2